Corrie Painter: Today, the company where I have been working since inception has emerged from stealth.

Corrie Painter, VP External Research & Partnerships at Precede Biosciences, shared the following post by Precede Biosciences, on LinkedIn, adding the following:

“I am thrilled to share some news with each of you in my network. Today, the company where I have been working since inception has emerged from stealth. It has been an incredible journey to work along side some of the most talented and dedicated people in industry to bring this technology into the world.
As many of you know, I am a long-term survivor of an exceedingly rare and aggressive cancer, and made a promise to myself the day of my diagnosis to spend whatever life I had left trying to bring impactful change to the lives of cancer patients. For the last year, I have been talking with many of you about the promise of this technology to transform precision medicine, and when I see your reactions , it makes me feel like I am making good on that promise.
My most heartfelt appreciation to each of you who have engaged with us so far, whether through guiding conversations or full blown collaborations. To those of you who would like to connect to discuss potential collaborations, please reach out!”

Quoting Precede Biosciences:

“Introducing our first-in-class liquid biopsy platform, a platform that finally unlocks the significant precision medicine opportunity space associated with transcriptionally regulated targets and pathways…all from a simple blood test, and specifically 1mL of plasma!

We believe that by understanding the fundamental biology behind disease at any given moment, developers and clinicians can better target medicines to the right patients.

Our platform is now collaboration ready. Learn more about Precede Biosciences.”

For details click here.
Source: Corrie Painter/LinkedIn and Precede Biosciences/LinkedIn